Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia veraHeinz Gisslinger, Richard Greil, Oleh Zagrijtschuk et al.|Blood|2015Cited by 186
Regulatory T cells predict the time to initial treatment in early stage chronic lymphocytic leukemiaLukas Weiß, Inge Tinhofer, Thomas Melchardt et al.|Cancer|2010Cited by 65
Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg‐proline‐interferon alpha‐2bNicole C.C. Them, Róbert Královics, Klaudia Bagienski et al.|American Journal of Hematology|2014Cited by 54
Long-Term Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Polycythemia Vera — Final Phase I/II Peginvera Study ResultsHeinz Gisslinger, Christoph Klade, Martin Schalling et al.|Blood|2018Cited by 18
A phase 1 study to evaluate the feasibility and efficacy of the addition of ropeginterferon alpha‐2b to imatinib treatment in patients with chronic phase chronic myeloid leukemia (CML) not achieving a deep molecular response (molecular remission 4.5)—AGMT_CML 1Sonja Heibl, Josef Thaler, Veronika Buxhofer‐Ausch et al.|Hematological Oncology|2020Cited by 11